DocDollars

Octapharma USA, Inc.

NJ · United States · Reporting entity ID 100000010699

Total reported 2019–2025
$19.1M
#331 of 2,960 reporting companies — 0% of all reported industry payments
$6.62M in general payments across 26,980 records, plus $12.5M in research funding across 1,339 records.

How it breaks down

General payments $6,619,364
Research funding $12,528,599

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Octapharma USA, Inc. reported $19.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #331 of 2,960 reporting companies. 65% of that was research funding and 35% general payments such as consulting, speaking, food and travel. 26,980 general payment records and 1,339 research records were filed.

Common questions about Octapharma USA, Inc.

How much has Octapharma USA, Inc. paid US doctors?

Octapharma USA, Inc. reported $19,147,964 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $6,619,364 in general payments, $12,528,599 in research funding.

How does Octapharma USA, Inc. rank among drug and device companies?

It ranks #331 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Octapharma USA, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.